Clinical trials
Lupus Erythematosus, Systemic clinical trials
Below are recruiting lupus erythematosus, systemic clinical trials, each written for real people, not researchers. We’re tracking 267 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07719140RecruitingPhase 4
Lower steroid dose study for children with lupus nephritis
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Beijing, Beijing MunicipalityAges 6–18 - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Mesa, ArizonaAges 16 years+ - NCT07276958RecruitingPhase 1
Study of LY4298445 for Lupus and Rheumatoid Arthritis
This trial tests a new drug called LY4298445 in healthy people and those with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how the body processes it.
BrisbaneAges 18–55 - NCT07355218RecruitingPhase 3
Testing enpatoran for lupus skin problems
This trial tests an oral drug called enpatoran for people with lupus that causes skin rashes (like discoid or subacute cutaneous lupus). The goal is to see if the drug can improve these skin symptoms.
Upland, CaliforniaAges 18–75 - NCT06917742RecruitingPhase 1
Study of CPTX2309 for rheumatoid arthritis and lupus
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Herston, QueenslandAges 18–65 - NCT03276923Recruiting
Pregnancy registry for women with autoimmune disease
This study is a pregnancy and health registry for women with autoimmune (immune system) conditions who are trying to become pregnant or are already pregnant. It helps researchers better understand pregnancy outcomes and health needs in autoimmune disease.
Durham, North CarolinaAges Any age - NCT03473912Recruiting
Rheumatoid disease biobank study for adults
This study asks adults with a rheumatoid condition to join a biobank, which is a safe place to store health information and biological samples for future research. It may help researchers better understand rheumatoid conditions and develop better treatments.
Kfar SabaAges 18–120 - NCT03543839RecruitingPhase 4
Belimumab for early lupus activity in the first two years
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Manhasset, New YorkAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT04320680Recruiting
Study visits for adults with lupus in Brest, France
This study focuses on people aged 18 and older with lupus who attend a multi-team clinic visit in Brest, France. It mainly looks at whether you can participate in the multidisciplinary consultation and its related study procedures.
BrestAges 18–80 - NCT04604990Recruiting
National lupus patient study for adults in Saudi Arabia
This study follows adults with systemic lupus erythematosus (lupus) to better understand the condition over time. If you meet common lupus diagnosis standards, you may be able to join—there’s no limit on when you were diagnosed.
Riyadh, Central ProvinceAges 19 years+ - NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT05007340Recruiting
ILD and autoimmune conditions registry and sample storage
This study collects health information and may store blood or other samples to learn more about interstitial lung disease (ILD) and autoimmune-related conditions. Joining could help researchers understand different causes of ILD and improve future care.
Montreal, QuebecAges 18 years+ - NCT05029336RecruitingPhase 2
Stem cell transplant using your own cells for autoimmune disease
This Phase 2 study tests an autologous stem cell transplant (a treatment using your own blood-forming stem cells) for severe systemic sclerosis or severe lupus. The goal is to reset the immune system to help control the autoimmune disease.
Philadelphia, PennsylvaniaAges 8–25 - NCT05193591Recruiting
Test antibodies in active lupus with kidney involvement
This study looks at specific immune antibodies (against C1s, HMGB1, and C1q) in adults with systemic lupus erythematosus, especially when lupus is actively affecting the kidneys. It may help researchers better understand what is driving active lupus and who could benefit from future treatments.
GrenobleAges 18 years+ - NCT05440422RecruitingPhase 2
Anifrolumab to improve blood vessel risk markers in lupus
This Phase 2 trial tests anifrolumab, a lupus medicine, to see if it can improve blood vessel “risk markers” in people with systemic lupus erythematosus (SLE). The study is especially focused on SLE-related problems that can affect heart and blood vessel health.
Bethesda, MarylandAges 18–80 - NCT05443516Recruiting
Blood and urine markers in active lupus kidney disease
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
BrusselsAges 18–70 - NCT05559671RecruitingPhase 4
Shingles vaccine safety study for people with lupus
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
New York, New YorkAges 18–90 - NCT05688696RecruitingPhase 2
Testing a drug called orelabrutinib for lupus symptoms in adults
This Phase 2 trial studies whether orelabrutinib can improve systemic lupus erythematosus (SLE) and check its safety. It may help people with active lupus who are already on stable lupus medicines.
Bengbu, AnhuiAges 18–75 - NCT05698173Recruiting
Study of lupus and accelerated aging
This study looks at how lupus relates to “accelerated aging” and may help researchers better understand disease effects over time. You might be able to join if you have systemic lupus and are able to consent and participate.
BordeauxAges 18–60 - NCT05714930Recruiting
Treating lupus symptoms to a clear goal
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT05859191Recruiting
Study of immune cell markers in people with lupus
This study looks at how certain immune cells (natural killer T cells) behave in people with systemic lupus, by measuring specific immune receptor markers in blood. It may help researchers better understand lupus and how it can connect with other conditions like antiphospholipid syndrome or Sjögren’s.
ToursAges 18 years+ - NCT05916781RecruitingPhase 4
Lowering steroids with mycophenolate and tacrolimus for lupus kidneys
This study tests whether using mycophenolate mofetil plus tacrolimus can help people with lupus nephritis safely lower (taper) their prednisone to a low dose. It is designed for people whose kidney lupus has been well-controlled for at least 6 months.
BeijingAges 18–65
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus erythematosus, systemic?
- Yes. Clin2 currently lists 267 recruiting lupus erythematosus, systemic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus, systemic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus, systemic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.